161 related articles for article (PubMed ID: 7753302)
21. Strategies to minimize bone disease in renal failure.
Martin KJ; González EA
Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
[TBL] [Abstract][Full Text] [Related]
22. Analysis of renal bone disease treatment in dialysis patients.
Johnson CA; McCarthy J; Bailie GR; Deane J; Smith S
Am J Kidney Dis; 2002 Jun; 39(6):1270-7. PubMed ID: 12046041
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.
Pettifor JM
Bone Miner; 1990 Jun; 9(3):199-214. PubMed ID: 2163713
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D analogs for the treatment of secondary hyperparathyroidism.
Slatopolsky E; Brown AJ
Blood Purif; 2002; 20(1):109-12. PubMed ID: 11803167
[TBL] [Abstract][Full Text] [Related]
25. Management of renal osteodystrophy in children.
Tasic V
Turk J Pediatr; 2005; 47 Suppl():13-8. PubMed ID: 15884662
[TBL] [Abstract][Full Text] [Related]
26. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
27. [Renal osteodystrophy].
Shoji T; Marumo F
Nihon Rinsho; 1993 Apr; 51(4):1011-6. PubMed ID: 8483256
[TBL] [Abstract][Full Text] [Related]
28. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy.
Hernandez JD; Wesseling K; Salusky IB
Semin Dial; 2005; 18(4):290-5. PubMed ID: 16076350
[TBL] [Abstract][Full Text] [Related]
29. Prevention of osteitis fibrosa, aluminium bone disease and soft-tissue calcification in dialysis patients: a long-term comparison of moderate doses of oral calcium +/- Mg(OH)2 vs Al(OH)3 +/- 1 alpha OH vitamin D3.
Morinière P; Boudailliez B; Hocine C; Belbrik S; Renaud H; Westeel PF; Solal MC; Fournier A
Nephrol Dial Transplant; 1989; 4(12):1045-53. PubMed ID: 2517325
[TBL] [Abstract][Full Text] [Related]
30. [Renal osteodystrophy Guidelines].
Messa P;
G Ital Nefrol; 2003; 20 Suppl 24():S83-95. PubMed ID: 14666505
[TBL] [Abstract][Full Text] [Related]
31. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of calcium carbonate and low-dose vitamin D/1,25(OH)2D3 in reducing the risk of developing renal osteodystrophy in children on continuous ambulatory peritoneal dialysis.
Jüppner H; Hoyer PF; Latta K; Winkler L; Offner G; Brodehl J
Pediatr Nephrol; 1990 Nov; 4(6):614-7. PubMed ID: 2088463
[TBL] [Abstract][Full Text] [Related]
33. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.
Delmez JA; Slatopolsky E
Am J Kidney Dis; 1992 Apr; 19(4):303-17. PubMed ID: 1562018
[TBL] [Abstract][Full Text] [Related]
34. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize?
Bro S; Brandi L; Daugaard H; Olgaard K
Perit Dial Int; 1997; 17(6):554-9. PubMed ID: 9655154
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of renal osteodystrophy: physiopathology and secondary effects].
Haldimann B; Flury W
Schweiz Med Wochenschr; 1977 Aug; 107(32):1113-8. PubMed ID: 333572
[TBL] [Abstract][Full Text] [Related]
36. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.
Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P
Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167
[TBL] [Abstract][Full Text] [Related]
37. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
38. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
Brandi L; Egfjord M; Olgaard K
Nephron Clin Pract; 2005; 99(4):c128-37. PubMed ID: 15722644
[TBL] [Abstract][Full Text] [Related]
39. Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy.
Fukushima M; Niki R; Ohkawa H; Shimizu T; Matsunaga I; Nakano H; Takagaki Y; Nishii Y; Okano K; Suda T
Endocrinology; 1980 Jul; 107(1):328-33. PubMed ID: 6247140
[TBL] [Abstract][Full Text] [Related]
40. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
